Nalaganje...

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Chemotherapy has historically proven toxic and ineffective for the treatment of metastatic hormone-refractory prostate cancer (HRPC), a disease with substantial morbidity and mortality. Progress has been made in symptom relief, and the combination of mitoxantrone and prednisone is considered the pal...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Glavni avtor: Petrylak, Daniel P
Format: Artigo
Jezik:Inglês
Izdano: MedReviews, LLC 2003
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC1502327/
https://ncbi.nlm.nih.gov/pubmed/16986041
Oznake: Označite
Brez oznak, prvi označite!